Literature DB >> 9744772

Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.

K Takasuna1, T Hagiwara, M Hirohashi, M Kato, M Nomura, E Nagai, T Yokoi, T Kamataki.   

Abstract

PURPOSE: SN-38, a metabolite of irinotecan hydrochloride (CPT-11), is considered to play a key role in the development of diarrhea as well as in the antitumor activity of CPT-11. We have previously found that the inhibition of beta-glucuronidase, which hydrolyzes detoxified SN-38 (SN-38 glucuronide) to reform SN-38, in the lumen by eliminating the intestinal microflora with antibiotics, markedly ameliorates the intestinal toxicity of CPT-11 in rats. In this study we compared the disposition of CPT-11 and its metabolites in rats treated with and without antibiotics.
METHODS: Rats were given drinking water containing 1 mg/ml penicillin and 2 mg/ml streptomycin from 5 days before the administration of CPT-11 (60 mg/kg i.v.) and throughout the experiment. CPT-11, SN-38 glucuronide and SN-38 concentrations in the blood, intestinal tissues and intestinal luminal contents were determined by HPLC.
RESULTS: Antibiotics had little or no effect on the pharmacokinetics of CPT-11, SN-38 glucuronide or SN-38 in the blood, or in the tissues or contents of the small intestine, which has less beta-glucuronidase activity in its luminal contents. In contrast, antibiotics markedly reduced the AUC1-24 h of SN-38 (by about 85%) in the large intestine tissue without changing that of CPT-11, and this was accompanied by a complete inhibition of the deconjugation of SN-38 glucuronide in the luminal contents.
CONCLUSIONS: These results suggest that SN-38, which results from the hydrolysis of SN-38 glucuronide by beta-glucuronidase in the intestinal microflora, contributes considerably to the distribution of SN-38 in the large intestine tissue, and that inhibition of the beta-glucuronidase activity by antibiotics results in decreased accumulation of SN-38 in the large intestine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744772     DOI: 10.1007/s002800050818

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

Review 1.  Drug-gut microbiota interactions: implications for neuropharmacology.

Authors:  Jacinta Walsh; Brendan T Griffin; Gerard Clarke; Niall P Hyland
Journal:  Br J Pharmacol       Date:  2018-06-28       Impact factor: 8.739

2.  Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.

Authors:  Masato Horikawa; Yukio Kato; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

Review 3.  Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics.

Authors:  Rachel N Carmody; Peter J Turnbaugh
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

Review 4.  Gut microbiome interactions with drug metabolism, efficacy, and toxicity.

Authors:  Ian D Wilson; Jeremy K Nicholson
Journal:  Transl Res       Date:  2016-08-13       Impact factor: 7.012

5.  Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity.

Authors:  Ren Kong; Timothy Liu; Xiaoping Zhu; Syed Ahmad; Alfred L Williams; Alexandria T Phan; Hong Zhao; John E Scott; Li-An Yeh; Stephen T C Wong
Journal:  Clin Cancer Res       Date:  2014-04-29       Impact factor: 12.531

Review 6.  Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies.

Authors:  Rachel J Gibson; Dorothy M K Keefe
Journal:  Support Care Cancer       Date:  2006-04-08       Impact factor: 3.603

7.  Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.

Authors:  Lisa M McGregor; Clinton F Stewart; Kristine R Crews; Michael Tagen; Amy Wozniak; Jianrong Wu; M Beth McCarville; Fariba Navid; Victor M Santana; Peter J Houghton; Wayne L Furman; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2011-04-20       Impact factor: 3.167

Review 8.  The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms.

Authors:  Kosuke Mima; Shuji Ogino; Shigeki Nakagawa; Hiroshi Sawayama; Koichi Kinoshita; Ryuichi Krashima; Takatsugu Ishimoto; Katsunori Imai; Masaaki Iwatsuki; Daisuke Hashimoto; Yoshifumi Baba; Yasuo Sakamoto; Yo-Ichi Yamashita; Naoya Yoshida; Akira Chikamoto; Takatoshi Ishiko; Hideo Baba
Journal:  Surg Oncol       Date:  2017-07-21       Impact factor: 3.279

Review 9.  Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.

Authors:  Umang Swami; Sanjay Goel; Sridhar Mani
Journal:  Curr Drug Targets       Date:  2013-06       Impact factor: 3.465

10.  Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity.

Authors:  Adam B Roberts; Bret D Wallace; Madhu Kumar Venkatesh; Sridhar Mani; Matthew R Redinbo
Journal:  Mol Pharmacol       Date:  2013-05-20       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.